CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH

该子项目是对CTSA供资的百分比的估计， 用于广泛的研究领域（艾滋病研究，儿科研究，或 临床试验）。 列出的总成本仅为CTSA金额的估算 基础设施走向这一领域的研究，而不是直接提供资金， 向子项目或子项目工作人员提供NCRR补助金。 描述（由申请人提供）：在过去的周期中，在与我们的内部和外部咨询委员会，组织治理结构和NCRR领导层协商后，我们将努力集中在两个首要主题上-转化治疗学和弥合儿科与成人的鸿沟，利用我们机构特有的资源。我们通过一系列“自上而下”和“自下而上”的资助举措促进了跨学科和转化研究。CTSA的支持和机构投资使ITMAT的足迹大幅增加了7倍以上，达到约150，000 nsf，其中包括一个扩展，整合和重新定位的临床和转化研究中心（CTRC），该中心继承了Penn和CHOP GCRC，干和湿实验室空间，一系列核心和ITMAT教育计划的新家。ITMAT还支持研讨会，研讨会和年度国际会议，突出CTSA在我们的校园提供的机会，以追求临床和转化研究。在过去的资助周期中，合作机构之间和内部的跨学科研究急剧增加，这些趋势在ITMAT成员中最为明显。在未来的周期中，我们设想我们的教育计划的持续增长和发展;继续扩大-通过招聘和教育-根据临床和转化研究的研究人员的临界质量;加强和扩大我们的核心基础设施，并开发和扩展专注于我们两个首要主题的计划。特别是，我们希望通过投射我们的两个战略目标来影响社区中的患者护理，通过整合基础，儿科和成人药理学的专业知识来改变当前的比较有效性研究范式，并为个性化医疗的预测策略做出贡献。 相关性（由申请人提供）：PENN，CHOP，Monell，Wistar研究所和费城科学大学从CTSA的第一轮资助中受益匪浅，该资助允许开发新的中心，研究项目，核心和强大的教育计划，涉及800多名研究人员跨校园和来自合作机构，以及增加全国性的财团活动。

This subproject represents an estimate of the percentage of the CTSA funding that is being utilized for a broad area of research (AIDS research, pediatric research, or clinical trials). The Total Cost listed is only an estimate of the amount of CTSA infrastructure going towards this area of research, not direct funding provided by the NCRR grant to the subproject or subproject staff. DESCRIPTION (provided by applicant): During the past cycle, following consultation with our internal and external advisory boards, organizational governance structure and the leadership of NCRR, we have focused our efforts on two overarching themes - Translational Therapeutics and Bridging the Pediatric to Adult Divide, taking advantage of resources particular to our institutions. We have fostered interdisciplinary and translational research by a series of "top down" and "bottom up" funding initiatives. CTSA support and institutional investment has increased dramatically the footprint of ITMAT more than 7 fold to ~150,000 nsf comprising an expanded, integrated and re-purposed Clinical and Translational Research Center (CTRC) that succeeds the Penn and CHOP GCRCs, dry and wet bench laboratory space, a series of cores and a new home for ITMAT educational programs. ITMAT also supports seminars, workshops and an annual international meeting highlighting the opportunities that the CTSA affords on our campus to pursue clinical and translational research. Interdisciplinary research has increased dramatically on, between, and within the partner institutions during the past funding cycle and these trends have been most pronounced amongst members of ITMAT. During the coming cycle we envisage the continued growth and development of our educational programs; the continued expansion - via recruitment and education - of the critical mass of investigators pursuant of clinical and translational research; enhancement and expansion of our core infrastructure and the development and expansion of programs focused on our two overarching themes. In particular we hope to impact patient care in the community by projecting our two strategic goals to alter the current paradigm of comparative effectiveness research by integrating expertise in basic, pediatric and adult pharmacology and to contribute to predictive strategies in the personalization of medicine. RELEVANCE (provided by applicant): PENN, CHOP, Monell, Wistar Institute, and the University of the Sciences of Philadelphia have benefited greatly from the first cycle of funding of the CTSA, which allowed the development of new centers, research programs, cores and a robust educational program which involve more than 800 investigators across campus and from partner institutions, as well as adding to consortial activities nationally.